Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275786 | 1.00 | AR (1.00) | ARKCNH2 | |
| SCHEMBL13965618 | 1.00 | AR (1.00) | ARKCNH2 | |
| SCHEMBL13656759 | 1.00 | AR (1.00) | ARKCNH2 | |
| SCHEMBL14336691 | 0.87 | AR (0.77) | ARKCNH2 | |
| SCHEMBL4799057 | 0.86 | AR (0.75) | ARKCNH2 | |
| SCHEMBL4799062 | 0.86 | AR (0.75) | ARKCNH2 | |
| SCHEMBL5116733 | 0.85 | AR (0.74) | ARKCNH2 | |
| SCHEMBL13403346 | 0.85 | AR (0.74) | ARKCNH2 | |
| SCHEMBL13403347 | 0.85 | AR (0.74) | ARKCNH2 | |
| SCHEMBL5874196 | 0.85 | AR (0.74) | ARKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605152-B2 | 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1467739-A4 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
| EP-1467739-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059293-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0880540-B1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | AVENTIS PHARMA INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6365597-B1 | FOR THERAPY OF ANDROGEN AND ESTROGEN MEDIATED DISORDERS, INCLUDING BENIGN PROSTATIC HYPERPLASIA, ANDROGEN MEDIATED PROSTATE CANCER, ESTROGEN MEDIATED BREAST CANCER AND ACNE | AVENTIS PHARMACEUTICALS INC. | 2002-04-02 | — | — | US | disclosed |
| EP-0880540-A1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | HOECHST MARION ROUSSEL, INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030069-A1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5237065-A | Steroid 5-alpha-reductase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0277002-B1 | STEROID-5-ALPHA-REDUCTASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-17 | — | — | EP | disclosed |
| US-5110939-A | Antiandrogens | SMITHKLINE BEECHAM CORPORATION (US) | 1992-05-05 | — | — | US | disclosed |
| US-4888336-A | DECREASE DIHYDROTESTOSTERONE ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0277002-A2 | Steroid-5-alpha-reductase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | SHBG, CYP19A1, NR5A1 | AR 6/4885KCNH2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.